AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

NCT04413201 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Non-squamous NSCLC

Interventions

DRUG: Afatinib
DRUG: Osimertinib

Sponsor

Michael Hopp

Collaborators

[object Object]